No profile data available.
Bicara Therapeutics Inc. (BCAX) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 103 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$137.95 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.16 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Bicara Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.16 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Tyra Biosciences, Inc. (TYRA), Replimune Group, Inc. (REPL), Oric Pharmaceuticals, Inc. (ORIC), Immatics N.v. (IMTX).